Alzheimer s & DementiaNeurosciencePeer-reviewed journal article
Large- Scale Deep Proteomic Analysis in Alzheimer's Disease Brain Regions Across Race and Ethnicity
Fatemeh SeifariD, Edward J. FoxiD, Anantharaman ShantaramaniD, Yue LiuiD, Eric B. DammeriD, Erica S. ModesteiD, Duc M. DuongiD, Luming Yin, Adam N. TrautwigiD, Qi Jin GuoiD, Kaiming XuiD, Lingyan PingiD, Joseph S. ReddyiD, Mariet AlleniD, Zachary QuicksalliD, Laura M. HeathiD, Jo Scanlan, Erming WangiD, Minghui WangiD, Abby Vander LindeniD, William L. PoehlmaniD, Xianfeng CheniD, Saurabh BahetiiD, Charlotte C.G. HoiD, Thuy NguyeniD, , Nicholas T. SeyfriediD
Abstract
AbstractO_ST_ABSIntroductionC_ST_ABSAlzheimers disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within the non-Hispanic White (NHW) population. Here we aimed to provide comprehensive insights into the proteomic landscape of AD across diverse racial and ethnic groups. MethodsDorsolateral prefrontal cortex (DLPFC) and superior temporal gyrus (STG) brain tissues were donated from multiple centers (Mayo Clinic, Emory University, Rush University, Mt. Sinai School of Medicine) and were harmonized through neuropathological evaluation, specifically adhering to the Braak staging and CERAD criteria. Among 1105 DLPFC tissue samples (998 unique individuals), 333 were from African American donors, 223 from Latino Americans, 529 from NHW donors, and the rest were from a mixed or unknown racial background. Among 280 STG tissue samples (244 unique individuals), 86 were African American, 76 Latino American, 116 NHW and the rest were mixed or unknown ethnicity. All tissues were uniformly homogenized and analyzed by tandem mass tag mass spectrometry (TMT-MS). ResultsAs a Quality control (QC) measure, proteins with more than 50% missing values were removed and iterative principal component analysis was conducted to remove outliers within brain regions. After QC, 9,180 and 9,734 proteins remained in the DLPC and STG proteome, respectively, of which approximately 9,000 proteins were shared between regions. Protein levels of microtubule-associated protein tau (MAPT) and amyloid-precursor protein (APP) demonstrated AD-related elevations in DLPFC tissues with a strong association with CERAD and Braak across racial groups. APOE4 protein levels in brain were highly concordant with APOE genotype of the individuals. DiscussionThis comprehensive region resolved large-scale proteomic dataset provides a resource for the understanding of ethnoracial-specific protein differences in AD brain.
- Citations
- 52
- FWCI
- 14.68
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease
Erica S. Modeste, Lingyan Ping, … Nicholas T. Seyfried·Molecular NeurodegenerationPeer-reviewed·Jul 19, 2023
- Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer's disease
Lingyan Ping, Sean R. Kundinger, … Nicholas T. Seyfried·Scientific DataPeer-reviewed·Sep 28, 2020
- Compilation of all known protein changes in the human Alzheimer's disease brain
Manor Askenazi, Tomas Kavanagh, … Eleanor Drummond·bioRxiv·Apr 13, 2023
- Unbiased Classification of the Human Brain Proteome Resolves Distinct Clinical and Pathophysiological Subtypes of Cognitive Impairment
Lenora A. Higginbotham, Kathleen Carter, … Nicholas T. Seyfried·bioRxiv·Jul 22, 2022
- Proteomic Subtyping of Alzheimer's Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic Biomarkers
Madison C. Bangs, Joshna Dharmendrabhai Gadhavi, … Nicholas T. Seyfried·Alzheimer s & DementiaPeer-reviewed·Nov 1, 2025
- Large-Scale Deep Multi-Layer Analysis of Alzheimer's Disease Brain Reveals Strong Proteomic Disease-Related Changes Not Observed at the RNA Level
Erik C. B. Johnson, Kathleen Carter, … Nicholas T. Seyfried·Nature NeurosciencePeer-reviewed·Feb 1, 2022